RESUMO
OBJECTIVE: Nausea and vomiting of pregnancy is a common disease that affects many women suffering from mild to severe symptoms. Amongst the different treatments, a fixed dose combination of doxylamine and pyridoxine has been proven safe and effective although the mechanism of action is not well established. There are different pharmaceutical dosage forms in the European market. The objective of this study was to compare the characteristics of a capsule formulation, Cariban® and a tablet formulation, Xonvea® to evaluate the potential impact of their release profiles on their onset of action. MATERIALS AND METHODS: 10 mg/10 mg of doxylamine succinate/pyridoxine hydrochloride capsules (Cariban®) and tablets (Xonvea®) were used as reference materials. Appearance, mass, composition, and in vitro dissolution profiles were compared. Bibliographic data from 4 pharmacokinetic studies of Xonvea® and 1 pharmacokinetic study of Cariban® was reviewed. RESULTS: In vitro dissolution studies showed significant differences in dissolution profiles of tablets and capsules. The later exhibiting some release of both drug substances in acid conditions followed by a non-complete release after a total of 3 hours while the tablets demonstrated gastro-resistant properties and rapid API release in about 20-30 minutes after the acid stage. Comparison of PK data showed greater Cmax for pyridoxine. CONCLUSIONS: At pH 6.8, complete and faster release of the fixed dose combination for Xonvea® gastro-resistant tablets compared to Cariban® capsules could possibly explain the greater Cmax observed in vivo for the tablet's formulation. This could translate into faster onset of action and relief of nausea for pregnant women taking the tablets vs. the capsules.
Assuntos
Antieméticos , Doxilamina , Feminino , Fármacos Gastrointestinais , Humanos , Náusea , Gravidez , Piridoxina , Solubilidade , ComprimidosRESUMO
Se obtuvieron microesferas de poli(D,L-láctico) conteniendo progesterona por medio de una emulsión simple aceite en agua empleando una técnica de evaporación de solvente. Se realizó un experimento con un diseño factorial 23 para estudiar el efecto de tres variables independientes (cantidad de principio activo, cantidad de polímero y concentración de alcohol polivinílico) sobre las variables dependientes (encapsulación de principio activo y tamaño de partícula). Las tres variables independientes influyeron significativamente sobre la encapsulación de progesterona. En el caso del tamaño de partícula, las variables que ejercieron una influencia significativa fueron la concentración de alcohol polivinílico y la cantidad de polímero. Los estudios de liberación in vitro han mostrado que de acuerdo al tamaño de partícula se pueden obtener formulaciones que logran liberar progesterona en pocos días u obtener una liberación sostenida durante 28 días. El estado físico del fármaco se investigó por calorimetría diferencial de barrido. Los estudios muestran que existe una interacción fisicoquímica entre la progesterona y el polímero
Microspheres of poly(D,L-lactide) containing progesterone were prepared by the solvent evaporation method using a simple oil water emulsion. 23 factorial design was used to determine the effect of three independent variables (amount of drug, amount of polymer and concentration of polyvinyl alcohol) over the dependent variables (drug content and particle size). The three independent variables influenced significantly over the percentage drug encapsulated. On the other hand, in the particle size case, the variables which produced a significantly influence were the polyvinyl alcohol concentration and the amount of polymer. The in vitro release studies have shown that according to the particle size, it can be obtained formulations which are able to release progesterone in a few days or a sustained release among 28 days. The physical state of drug has been examined by differential scanning calorimetric. The studies indicate that exists a physicochemical interaction between the progesterone and the polymer
